Evidence map›Paper›PMID 30541620›Full record

ArticleActa neuropathologica communications2018

Mitochondrial transfer from mesenchymal stem cells to neural stem cells protects against the neurotoxic effects of cisplatin.

Nabila Boukelmoune, Gabriel S Chiu, Annemieke Kavelaars, Cobi J Heijnen

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta neuropathologica communications, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 94 papers.

0numbers the graph read from it
0cells of the map it votes in
94citing papers in PubMed
9.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

94 citing papers in PubMed, 157 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review

34 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Nabila BoukelmouneLaboratory of Neuroimmunology, Department of Symptom Research, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 384, Houston, TX, 77030, USA.
Gabriel S ChiuLaboratory of Neuroimmunology, Department of Symptom Research, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 384, Houston, TX, 77030, USA.
Annemieke KavelaarsLaboratory of Neuroimmunology, Department of Symptom Research, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 384, Houston, TX, 77030, USA.
Cobi J HeijnenLaboratory of Neuroimmunology, Department of Symptom Research, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 384, Houston, TX, 77030, USA. cjheijnen@mdanderson.org.ORCID 0000-0002-1928-3050
The University of Texas MD Anderson Cancer Center · US

Funding

A3AR agonists as a novel approach to mitigate chemotherapy induced neurotoxicityR01CA230512 · NCI · SAINT LOUIS UNIVERSITY · PI SALVEMINI, DANIELA · 2018 to 2022
$2.8M
Mesenchymal Stem Cells to Repair ChemobrainR01CA208371 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI HEIJNEN, COBI J, SHEPHERD, ANDREW JOHN · 2016 to 2020
$2.4M
PQ12 Targeting HDAC6 for Chemotherapy-Induced Neuropathy and ChemobrainR01CA227064 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI GRACE, PETER M, SHEPHERD, ANDREW JOHN · 2018 to 2023
$2.2M
NCI NIH HHS R01 CA208371NCI NIH HHS R01 CA227064NCI NIH HHS R01 CA230512
6 · The paper itself

Abstract

Mesenchymal stem cells (MSCs) transfer healthy mitochondria to damaged acceptor cells via actin-based intercellular structures. In this study, we tested the hypothesis that MSCs transfer mitochondria to neural stem cells (NSCs) to protect NSCs against the neurotoxic effects of cisplatin treatment. Our results show that MSCs donate mitochondria to NSCs damaged in vitro by cisplatin. Transfer of healthy MSC-derived mitochondria decreases cisplatin-induced NSC death. Moreover, mitochondrial transfer from MSCs to NSCs reverses the cisplatin-induced decrease in mitochondrial membrane potential. Blocking the formation of actin-based intercellular structures inhibited the transfer of mitochondria to NSCs and abrogated the positive effects of MSCs on NSC survival. Conversely, overexpression of the mitochondrial motor protein Rho-GTPase 1 (Miro1) in MSCs increased mitochondrial transfer and further improved survival of cisplatin-treated NSCs.In vivo, MSC administration prevented the loss of DCX+ neural progenitor cells in the subventricular zone and hippocampal dentate gyrus which occurs as a result of cisplatin treatment. We propose mitochondrial transfer as one of the mechanisms via which MSCs exert their therapeutic regenerative effects after cisplatin treatment.

Indexed as

AnimalsBridged Bicyclo Compounds, HeterocyclicCarbonyl Cyanide p-TrifluoromethoxyphenylhydrazoneCells, CulturedCerebral CortexCholera ToxinCisplatinDoublecortin Domain ProteinsDoublecortin ProteinEnergy MetabolismEnzyme InhibitorsMaleMembrane Potential, MitochondrialMesenchymal Stem CellsMiceMice, Inbred C57BLBridged Bicyclo Compounds, HeterocyclicCarbonyl Cyanide p-TrifluoromethoxyphenylhydrazoneCholera ToxinCisplatinDcx protein, mouseDoublecortin Domain ProteinsDoublecortin ProteinEnzyme Inhibitorslatrunculin BMicrotubule-Associated ProteinsNeuropeptidesNeurotoxinsOligomycinsThiazolidinesWheat Germ AgglutininsCisplatinMesenchymal stem cellsMitochondrial transferNeuronal stem cells

Identifiers

PMID30541620
PMCPMC6292021
OpenAlexW2904921001

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.